Akèy › Sakom Ewing › Massachusetts
Etid klinik pou Sakom Ewing nan Massachusetts
6 etid pou Sakom Ewing ap chèche patisipan nan sit nan Massachusetts.
Vil nan Massachusetts
Tèks ofisyèl etid la (Anglè)
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 2 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07297979Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Dana-Farber Cancer Institute ( Site 1013), Boston
Ap rekriteFaz 1/2
6 Months – 25 Years · Tout sèks · Mizajou Sep 17, 2026 · NCT06395103Lurbinectedin in FET-Fused Tumors
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 10 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT05918640Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
12 Months – 30 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT04851119A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
- Mass General Brigham Cancer Institute, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 16 ak plis · Tout sèks · Mizajou Jun 2, 2026 · NCT07197554Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
Ap rekriteFaz 1/2
Laj 12 a 49 · Tout sèks · Mizajou Feb 19, 2026 · NCT06709495Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.